Page last updated: 2024-12-07

dup 734

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

DuP 734: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID121967
SCHEMBL ID467156
MeSH IDM0211041

Synonyms (18)

Synonym
ethanone, 2-(1-(cyclopropylmethyl)-4-piperidinyl)-1-(4-fluorophenyl)-, hydrobromide
1-(cyclopropylmethyl)-4-(2'-(4''-fluorophenyl)-2'-oxoethyl)piperidine
dup 734
dup-734
2-[1-(cyclopropylmethyl)piperidin-4-yl]-1-(4-fluorophenyl)ethanone hydrobromide
135135-87-4
c37356qt0j ,
unii-c37356qt0j
ethanone, 2-(1-(cyclopropylmethyl)-4-piperidinyl)-1-(4-fluorophenyl)-, hydrobromide (1:1)
SCHEMBL467156
dup734
DTXSID40159263
2-[1-(cyclopropylmethyl)piperidin-4-yl]-1-(4-fluorophenyl)ethanone;hydrobromide
HY-136281
CS-0127541
Q27275133
MS-25572
AKOS040755615

Research Excerpts

Actions

ExcerptReferenceRelevance
"DuP 734 did not inhibit the synaptosomal uptake of dopamine, 5-HT or norepinephrine."( DuP 734 [1-(cyclopropylmethyl)-4-(2'(4''-fluorophenyl)-2'-oxoethyl)- piperidine HBr], a sigma and 5-hydroxytryptamine2 receptor antagonist: receptor-binding, electrophysiological and neuropharmacological profiles.
Cook, L; Gilligan, PJ; Schmidt, WK; Steinfels, GF; Tam, SW, 1992
)
2.45

Pharmacokinetics

ExcerptReferenceRelevance
" The terminal elimination half-life ranged from 50 to 83 min."( Dose and species dependent pharmacokinetics of a novel sigma receptor antagonist, DuP 734.
Kapil, RP; Lam, GN, 1995
)
0.52
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (6)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Sigma non-opioid intracellular receptor 1Mus musculus (house mouse)Ki0.01000.00190.20180.8200AID204597
5-hydroxytryptamine receptor 2C Mus musculus (house mouse)Ki0.01500.00080.50322.8420AID5025
5-hydroxytryptamine receptor 2AMus musculus (house mouse)Ki0.01500.00080.65892.8420AID5025
D(2) dopamine receptorMus musculus (house mouse)IC50 (µMol)1.63000.00090.47332.4310AID61051
5-hydroxytryptamine receptor 2BMus musculus (house mouse)Ki0.01500.00080.65892.8420AID5025
DMus musculus (house mouse)Ki1.00000.00040.76232.5300AID63358
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (15)

Assay IDTitleYearJournalArticle
AID204597In vitro binding affinity for the mouse sigma opioid receptor1992Journal of medicinal chemistry, Nov-13, Volume: 35, Issue:23
Novel piperidine sigma receptor ligands as potential antipsychotic drugs.
AID176445Oral potency by using Anti aggression test1992Journal of medicinal chemistry, Nov-13, Volume: 35, Issue:23
Novel piperidine sigma receptor ligands as potential antipsychotic drugs.
AID131404Oral potency tested using apomorphine induced climbing test1992Journal of medicinal chemistry, Nov-13, Volume: 35, Issue:23
Novel piperidine sigma receptor ligands as potential antipsychotic drugs.
AID204462Binding affinity for sigma receptor of guinea pig whole brain using [3H]-SKF- 100047 radioligand1994Journal of medicinal chemistry, Feb-04, Volume: 37, Issue:3
Piperidinyltetralin sigma ligands.
AID5025In vitro binding affinity for serotonin 5-hydroxytryptamine (5-HT) 2 receptors1992Journal of medicinal chemistry, Nov-13, Volume: 35, Issue:23
Novel piperidine sigma receptor ligands as potential antipsychotic drugs.
AID131403Oral potency tested by using anti-mescaline test1992Journal of medicinal chemistry, Nov-13, Volume: 35, Issue:23
Novel piperidine sigma receptor ligands as potential antipsychotic drugs.
AID225350Antimescaline activity in the mouse (administered po)1994Journal of medicinal chemistry, Feb-04, Volume: 37, Issue:3
Piperidinyltetralin sigma ligands.
AID176613In vivo 5-HT2 antagonism of 5-HTP-induced head twitch in rat1994Journal of medicinal chemistry, Feb-04, Volume: 37, Issue:3
Piperidinyltetralin sigma ligands.
AID5011Binding affinity for serotonin 5-hydroxytryptamine 2 receptor using [3H]ketanserin in guinea pig frontal cortex1994Journal of medicinal chemistry, Feb-04, Volume: 37, Issue:3
Piperidinyltetralin sigma ligands.
AID62740Binding affinity for dopamine D2 receptor using [3H]spiperone in guinea pig striatum1994Journal of medicinal chemistry, Feb-04, Volume: 37, Issue:3
Piperidinyltetralin sigma ligands.
AID225345Ability to block the aggressive behavior caused by prolonged isolation in mouse1994Journal of medicinal chemistry, Feb-04, Volume: 37, Issue:3
Piperidinyltetralin sigma ligands.
AID61051In vitro binding affinity towards dopamine receptor D21992Journal of medicinal chemistry, Nov-13, Volume: 35, Issue:23
Novel piperidine sigma receptor ligands as potential antipsychotic drugs.
AID176444Oral potency tested using 5HTP induced head twitch test1992Journal of medicinal chemistry, Nov-13, Volume: 35, Issue:23
Novel piperidine sigma receptor ligands as potential antipsychotic drugs.
AID63358The compound was tested in vitro for its binding affinity towards dopamine receptor D11992Journal of medicinal chemistry, Nov-13, Volume: 35, Issue:23
Novel piperidine sigma receptor ligands as potential antipsychotic drugs.
AID180368The compound was tested for blocking the rotation induced by (+)-SKF 10047 in brain-lesioned rats.1992Journal of medicinal chemistry, Nov-13, Volume: 35, Issue:23
Novel piperidine sigma receptor ligands as potential antipsychotic drugs.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (22)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's21 (95.45)18.2507
2000's1 (4.55)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 10.89

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index10.89 (24.57)
Research Supply Index3.26 (2.92)
Research Growth Index4.15 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (10.89)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other25 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]